Research

Interim Results of Ongoing Clinical Trials May Be Misleading

Interim Results of Ongoing Clinical Trials May Be Misleading

By

Published interim results of ongoing clinical trials often report analyses without justification and may mislead clinicians about whether a particular drug or therapy is beneficial.

Clinical Trials May Overestimate Benefits of Cannabis Therapy

Clinical Trials May Overestimate Benefits of Cannabis Therapy

By

The benefits associated with medical cannabis therapy may be overestimated due to inadequate blinding in clinical trials.

Pharmaceutical, Medical Device Companies Fight Unfavorable Trial Results

Pharmaceutical, Medical Device Companies Fight Unfavorable Trial Results

By

Scientists continue to be the targets of legal action from pharmaceutical, medical device, and nutraceutical companies when published studies frame these companies' products in an unfavorable light.

New SLE Candidate Criteria

New SLE Candidate Criteria

By

Researchers have created a set of 21 candidate criteria for systemic lupus erythematosus as apart of a multiphase development of a set of criteria for the disease.

RFP From the Lupus Foundation of America

RFP From the Lupus Foundation of America

The Lupus Foundation of America announced it is accepting applications for 8 research grants to fund lupus research.

National Academies Report on Health Effects of Cannabis

National Academies Report on Health Effects of Cannabis

By

In January 2017, the National Academies of Sciences, Engineering, and Medicine released a report titled "The Health Effects of Cannabis and Cannabinoids: The Current State of Evidence and Recommendation for Research."

What the Scheduling of Kratom by the DEA Means for Research

What the Scheduling of Kratom by the DEA Means for Research

By

The DEA's plan to list kratom as a Schedule I controlled substance would make researching the possible opioid substitute much more difficult.

Sign Up for Free e-Newsletters